NYSE:EW

Edwards Lifesciences (EW) Stock Price, News & Analysis

Edwards Lifesciences logo
$105.17 -0.26 (-0.25%)
Closing price 03:59 PM Eastern
Extended Trading
$105.06 -0.11 (-0.11%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Edwards Lifesciences Stock (NYSE:EW)

Advanced

Key Stats

Today's Range
$103.07
▼
$106.56
50-Day Range
$84.18
▼
$107.16
52-Week Range
$74.66
▼
$108.00
Volume
3.92 million shs
Average Volume
4.53 million shs
Market Capitalization
$60.47 billion
P/E Ratio
59.42
Dividend Yield
N/A
Price Target
$109.88
Consensus Rating
Moderate Buy

Company Overview

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery.

The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

Its structural heart portfolio includes transcatheter aortic valve replacement (TAVR) systems and therapies addressing mitral and tricuspid valve disease. Bernard Zovighian became the company’s chief executive officer in 2023.

AI Generated. May Contain Errors.

Edwards Lifesciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

EW MarketRank™: 
3.017939034255 of 5 stars

Edwards Lifesciences scored higher than 60% of companies evaluated by MarketBeat, and ranked 721st out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Edwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on no strong buy ratings, 23 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Edwards Lifesciences is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Edwards Lifesciences has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Edwards Lifesciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Edwards Lifesciences are expected to grow by 12.96% in the coming year, from $3.01 to $3.40 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Edwards Lifesciences is 59.42, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.92.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Edwards Lifesciences is 59.42, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.58.

  • Price to Earnings Growth Ratio

    Edwards Lifesciences has a PEG Ratio of 2.86. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Edwards Lifesciences has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.64% of the float of Edwards Lifesciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Edwards Lifesciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Edwards Lifesciences has recently increased by 0.52%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Edwards Lifesciences does not currently pay a dividend.

  • Dividend Growth

    Edwards Lifesciences does not have a long track record of dividend growth.

  • News Sentiment

    Edwards Lifesciences has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Edwards Lifesciences this week, compared to 8 articles on an average week.
  • Search Interest

    14 people have searched for EW on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,498,306.00 in company stock.

  • Percentage Held by Insiders

    0.31% of the stock of Edwards Lifesciences is held by insiders.

  • Percentage Held by Institutions

    79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Edwards Lifesciences' insider trading history.
Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EW Stock News Headlines

Buy Stocks… A Crash is Coming
Think stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.tc pixel
Should You Book Profits or Hold BSX Stock Post-Q3 Earnings?
Edwards Lifesciences (NYSE:EW) Price Target Raised to $121.00
See More Headlines

EW Stock Analysis - Frequently Asked Questions

Edwards Lifesciences' stock was trading at $85.26 on January 1st, 2026. Since then, EW stock has increased by 23.3% and is now trading at $105.1680.

Edwards Lifesciences Corporation (NYSE:EW) posted its earnings results on Wednesday, November, 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.06. Edwards Lifesciences's revenue was up 10.5% compared to the same quarter last year.
Read the conference call transcript
.

Edwards Lifesciences's stock split on the morning of Friday, May 29th 2020.The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were payable to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Edwards Lifesciences subsidiaries include CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and others.

Top institutional shareholders of Edwards Lifesciences include State Street Corp (4.62%), Ninety One UK Ltd (2.07%), Goldman Sachs Group Inc. (0.94%) and Assenagon Asset Management S.A. (0.47%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Kieran Gallahue, Steven R Loranger, Bernard J Zovighian, Daniel J Lippis, Scott B Ullem, Catherine M Szyman, Daveen Chopra, Heisz Leslie Stone, Donald E Bobo Jr, Annette Bruls, Andrew M Dahl, Robert WA Sellers, Wayne Markowitz and Michael A Mussallem.
View institutional ownership trends
.

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include NVIDIA (NVDA), Salesforce (CRM), Adobe (ADBE), Visa (V), Mastercard (MA), Broadcom (AVGO) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/04/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NYSE:EW
CIK
1099800
Employees
16,000
Year Founded
1958

Price Target and Rating

High Price Target
$121.00
Low Price Target
$85.00
Potential Upside/Downside
+4.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
26 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.77
Trailing P/E Ratio
59.42
Forward P/E Ratio
30.93
P/E Growth
2.86
Net Income
$1.07 billion
Net Margins
15.30%
Pretax Margin
21.46%
Return on Equity
16.06%
Return on Assets
12.36%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
4.60
Quick Ratio
3.86

Sales & Book Value

Annual Sales
$6.07 billion
Price / Sales
9.97
Cash Flow
$2.80 per share
Price / Cash Flow
37.56
Book Value
$19.06 per share
Price / Book
5.52

Miscellaneous

Outstanding Shares
575,000,000
Free Float
573,218,000
Market Cap
$60.47 billion
Optionable
Optionable
Beta
0.85

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NYSE:EW) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners